tetano
Editor, Senior Moderator
Published ahead of print 26 December 2013, doi: 10.1128/JVI.01829-13 JVI.01829-13
Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets
Grace L Chen1,
Elaine W Lamirande1,
Xing Cheng2,
Fernando Torres-Velez3,
Marlene Orandle3,
Hong Jin2,
George Kemble2 and
Kanta Subbarao1*
+ Author Affiliations
1Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892
2MedImmune, Mountain View, CA 94043
3Comparative Medicine Branch, NIAID, NIH, Rockville, MD 20892
ABSTRACT
H2 influenza viruses have not circulated in humans since 1968 and therefore a significant portion of the population would be susceptible to infection should H2 influenza viruses re-emerge. H2 influenza viruses continue to circulate in avian reservoirs worldwide and these reservoirs are a potential source from which these viruses could emerge. Three reassortant cold-adapted (ca) H2 pandemic influenza vaccine candidates with HA and NA genes derived from the wild-type A/Japan/305/1957 (H2N2) (Jap/57), A/mallard/6750/1978 (H2N2) (mal/78), or A/swine/MO/4296424/2006 (H2N3) (sw/06) viruses and the internal protein gene segments from the A/Ann Arbor/6/60 ca virus were generated by plasmid-based reverse genetics (Jap/57 ca, mal/78 ca and sw/06 ca, respectively). The vaccine candidates exhibited the in vitro phenotypes of temperature sensitivity and cold adaptation and were restricted in replication in the respiratory tract of ferrets. In mice and ferrets, the vaccines elicited neutralizing antibodies and conferred protection against homologous wild-type virus challenge. Of the three candidates, the sw/06 ca vaccine elicited cross-reactive antibodies and provided significant protection against the greatest number of heterologous viruses. These observations suggest that the sw/06 ca vaccine should be further evaluated in a clinical trial as a H2 pandemic influenza vaccine candidate.
http://jvi.asm.org/content/early/2013/12/20/JVI.01829-13.abstract
Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets
Grace L Chen1,
Elaine W Lamirande1,
Xing Cheng2,
Fernando Torres-Velez3,
Marlene Orandle3,
Hong Jin2,
George Kemble2 and
Kanta Subbarao1*
+ Author Affiliations
1Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892
2MedImmune, Mountain View, CA 94043
3Comparative Medicine Branch, NIAID, NIH, Rockville, MD 20892
ABSTRACT
H2 influenza viruses have not circulated in humans since 1968 and therefore a significant portion of the population would be susceptible to infection should H2 influenza viruses re-emerge. H2 influenza viruses continue to circulate in avian reservoirs worldwide and these reservoirs are a potential source from which these viruses could emerge. Three reassortant cold-adapted (ca) H2 pandemic influenza vaccine candidates with HA and NA genes derived from the wild-type A/Japan/305/1957 (H2N2) (Jap/57), A/mallard/6750/1978 (H2N2) (mal/78), or A/swine/MO/4296424/2006 (H2N3) (sw/06) viruses and the internal protein gene segments from the A/Ann Arbor/6/60 ca virus were generated by plasmid-based reverse genetics (Jap/57 ca, mal/78 ca and sw/06 ca, respectively). The vaccine candidates exhibited the in vitro phenotypes of temperature sensitivity and cold adaptation and were restricted in replication in the respiratory tract of ferrets. In mice and ferrets, the vaccines elicited neutralizing antibodies and conferred protection against homologous wild-type virus challenge. Of the three candidates, the sw/06 ca vaccine elicited cross-reactive antibodies and provided significant protection against the greatest number of heterologous viruses. These observations suggest that the sw/06 ca vaccine should be further evaluated in a clinical trial as a H2 pandemic influenza vaccine candidate.
http://jvi.asm.org/content/early/2013/12/20/JVI.01829-13.abstract